Low frequency of programmed death ligand 1 expression in pediatric cancers

T Aoki, M Hino, K Koh, M Kyushiki… - Pediatric blood & …, 2016 - Wiley Online Library
T Aoki, M Hino, K Koh, M Kyushiki, H Kishimoto, Y Arakawa, R Hanada, H Kawashima…
Pediatric blood & cancer, 2016Wiley Online Library
Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway blockade has
become a promising therapeutic target in adult cancers. We evaluated PD‐L1 expression
and tumor‐infiltrating CD8+ T cells in formalin‐fixed, paraffin‐embedded tumor specimens
from 53 untreated pediatric patients with eight cancer types: neuroblastoma, extracranial
malignant germ cell tumor, hepatoblastoma, germinoma, medulloblastoma, renal tumor,
rhabdomyosarcoma, and atypical teratoid/rhabdoid tumor. One rhabdomyosarcoma with the …
Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway blockade has become a promising therapeutic target in adult cancers. We evaluated PD‐L1 expression and tumor‐infiltrating CD8+ T cells in formalin‐fixed, paraffin‐embedded tumor specimens from 53 untreated pediatric patients with eight cancer types: neuroblastoma, extracranial malignant germ cell tumor, hepatoblastoma, germinoma, medulloblastoma, renal tumor, rhabdomyosarcoma, and atypical teratoid/rhabdoid tumor. One rhabdomyosarcoma with the shortest survival exhibited membranous PD‐L1 expression and germinoma contained abundant tumor‐infiltrating CD8+ T cells and PD‐L1‐positive macrophages. The PD‐1/PD‐L1 pathway tended to be inactive in pediatric cancers.
Wiley Online Library